Poseida Therapeutics guns again for IPO

Nasdaq
(Nasdaq)

After ditching an attempted IPO earlier this year in favor of another funding round, CAR-T biotech Poseida Therapeutics is happy to go again.

In April last year, the cell therapy player put the kibosh on original its IPO plans, settling instead for a $142 million series C round with more than half of the money coming from cell and gene therapy devotee Novartis.

The Big Pharma put up a $75 million equity investment in the San Diego-based company, which has a stable of CAR-T candidates manufactured through a nonviral process.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

At the time, Poseida CEO Eric Ostertag told Fierce Biotech: “This plan was initially delayed due to the government shutdown, then delayed again to refile financials that went stale during the wait. Throughout the course of these delays, we continued prior conversations with strategic interests, one of which was Novartis.”

The company had planned to file an IPO again later in 2019, but it's now doing so more than a year later in the middle of a pandemic that has, oddly, been a boon for biotech IPOs.

It’s looking for $115 million, with much of that earmarked for the company's leading candidate P-BCMA-101, an autologous CAR-T currently in a potentially registrational phase 2 trial for multiple myeloma.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.